In this phase II study, the combination regimen was well tolerated, producing no grade 3/4 treatment-related adverse events.
In this individual patient data meta-analysis of 5 clinical trials, gemtuzumab ozogamicin reduced relapse risk improving survival in patients with more favorable cytogenetics.
ARRY-614 appears effective in both newly diagnosed patients with MDS and those previously treated with a hypomethylating agent.
Cytogenetic abnormalities at the onset of AZA treatment in patients with high-risk MDS were predictive of survival but generally not cytogenetic response, and cytogenetic response had no effect on outcome.
An improved safety profile was observed with lower-dose quizartinib vs higher doses in a previous study, specifically with lowering of QT prolongation rate, while achieving an equivalent bridging of patients to HSCT.
Results of this randomized phase II trial demonstrate comparable efficacy and pharmacodynamics for 60- and 90-mg/m2 doses and an acceptable toxicity profile.
Molecular analyses of patient samples obtained before and after diagnosis of therapy-related AML and therapy-related MDS provide a model to explain the poor chemotherapy response and excess TP53 mutations typically associated with this disease.
In this phase I/II study of elderly patients with very poor cytogenetic factors (eg, del[5q], complex karyotype), 46% achieved CR with most responders also achieving cytogenetic response; however, median DFS was only 6 months.
In this pilot study, extreme adverse events, including cytokine secretion and ferritin elevation, were observed in 25% of patients who received the CAR-expressing CTL019 T-cell infusion but were easily resolved with a single dose of tocilizumab.
A phase I study of CD19-targeted T-cell therapy demonstrated CR rates > 75% in patients with minimal residual disease or morphologic residual disease with most eligible patients undergoing subsequent allo-SCT.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.